Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran versus enoxaparin for venous thromboembolism prevention after elective total knee replacement
2005-001998-10Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2005
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dabigatran and enoxaparin in venous thromboembolism (VTE) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Primary efficacy endpoint. Started Jul 2005; status: completed.
02
Drugs
dabigatranenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2005-001998-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001998-10.